JUUL Attorney

JUUL Health Problems

Have you been juuling and experienced any of these health problems?

  • Addiction
  • Seizures
  • Strokes
  • Lung Problems including higher asthma attacks
  • Respiratory problems

You were targeted by JUUL. Your addiction and health problems are not your fault. Our attorneys are taking clients who have experienced any of these health problems. You don’t pay anything unless we win your case. If you or a loved one who was previously not a smoker experienced any of these problems, please call our JUUL lawyers at 1-844-266-9468 for a free case evaluation. You could have a claim against the JUUL manufacturers.

JUUL & Vaping Lawsuit

Teenagers, adolescents and young adults were targeted consumers by JUUL, the largest maker of e-cigarettes. The vaping company marketed on specific social media channels with younger demographics. The JUUL pod flavors were sweet and candy-like, appealing to the youth, not older adults. Now our youth are addicted to vaping e-cigarettes and are experiencing severe health problems. If you are addicted to JUUL, please seek help to stop vaping.

Our JUUL lawyers at Laminack, Pirtle & Martines are talking to individuals to determine if they have a lawsuit claim against JUUL. If you or a loved one started JUULing without previously smoking cigarettes and experienced health problems including addiction, seizures, strokes and lung problems, please call our vaping attorneys today at 1-844-266-9468. Our JUUL attorneys do not charge any fees unless we win your case.

Laminack, Pirtle & Martines attorneys have won millions for their clients  against major companies including pharmaceutical manufacturers, medical device manufacturers, energy companies and more.   Their proven experience in and out of the courtroom ensures your case will be handled with the utmost integrity. All vaping and JUUL cases are handled individually and are not part of a class-action lawsuit. Call us today at 1-844-266-9468.

FACTS ABOUT JUULING, VAPING AND E-CIGARETTES

  • E-cigarettes usage is HIGHER IN YOUTH THAN ADULTS
  • All JUUL flavors contain nicotine 
  • One JUUL vaping pod contains more nicotine than an entire pack of cigarettes 
  • JUUL intake is through aerosol, not actually a vapor
  • Aerosol contains tiny chemical particles
  • Nicotine in JUUL damages adolescent brains and causes addiction
  • For every 1 adult who stops smoking due to vaping, 81 kids start vaping.
  • Brains are still developing until about 25 years old.  See Surgeon General report. 
  • 1 in 5 high school kids vape using JUUL or other e-cigarette products.
  • From 2017 to 2018, e-cigarette use in high school kids increased by 78%.
  • 1 in 20 middle school kids vape 
  • From 2017 to 2018, e-cigarette use increased by 48% in middle school kids.
  • “The Surgeon General has concluded that e-cigarette use among youths and young adults is of public health concern; exposure to nicotine during adolescence can cause addiction and can harm the developing adolescent brain.”  CDC Report
  • Fruit-flavored JUUL pods are still available online 
  • JUUL invested tens of thousands of dollars to get in the doors of schools, claiming it was anti-nicotine program.  Teachers were asked to leave the classroom for the presentations. JUUL showed their products, exposing the youth to e-cigarettes and claiming it was safe.  
  • JUUL CEO Kevin Burns admits during an interview with CBS News that JUUL does not know the long-term effects of vaping. 

JUUL HISTORY & TIMELINE

While JUUL has recently been in the news, the history of the e-cigarette product dates back more than 12 years.  Here’s a JUUL timeline from launch to now.

June 2007: Ploom, Inc. is founded by James Monsees and Adam Bowen and begins marketing Pax Vaporizers.  They became billionaires in late 2018.

May 5, 2011: Ploom, Inc. officially changes name to Pax Labs, Inc.

April 7, 2015: JUUL Labs, Inc. formed.

June 1, 2015: The JUUL is first introduced into the market by Pax Labs.  The JUUL is an e-cigarette product for vaping.

June 2015 –  November 2018:  JUUL floods Social Media sites Facebook, Instagram, Twitter, and YouTube with marketing ads designed to target young adults and minors, using young models and celebrity influencers.   JUUL even launched campaigns handing out FREE JUUL devices.

June 2017: Adam Bowen & James Monsees officially leave Pax Labs

July 2017: JUUL Labs is spun out of Pax Labs as independent company.  Monsees becomes Chief Product Officer.  Bowen becomes Chief Technology Officer.

April 24, 2018: FDA demands JUUL Labs produce documents regarding JUUL’s marketing practices, market research, product design, public health impact, adverse events and complaints related to JUUL.

4/17/18: American Academy of Pediatrics Posts warning on website to parents regarding the dangers of JUUL

9/12/2018: FDA Conducts  the Largest Coordinated Enforcement Activity in its History – 1300 Retail Stores Illegally Selling JUUL, and other e-Cig, Devices to Minors Issued Civil Penalties and Official Warning Letters

9/12/2018: FDA sends letter to JUUL demanding the company ‘take prompt action to address the rate of youth use of JUUL products.’; Demands ‘detailed plan to address and mitigate widespread use by minors.’; Demands ‘removing flavored products from the market…’

September 28, 2018: FDA conducts unannounced inspection of JUUL Labs, Inc.; Seizes 1,000’s of documents in latest e-cigarette crackdown.

10/2/2018: The Centers for Disease Control Issues Press Release on the Dangers of JUUL

November 18, 2018: Under pressure from FDA and Medical Organizations, JUUL halts retail sales of flavored JUUL pods; Exits social media, discontinuing Facebook and Instagram accounts.

December 18, 2018: U.S. Surgeon General releases Advisory on E-cigarette Epidemic Among Youth;  “We must take action now to protect the health of our nation’s young people.”

12/20/18: Altria (previously known as Philip Morris Companies, Inc.) Invests $12.8 Billion in JUUL for 35% of JUUL Labs

2/6/2019: FDA send letter to JUUL demanding meeting following Altria’s acquisition of major ownership of JUUL; Notice given to JUUL that its actions are inconsistent with previous representations made to the FDA concerning addressing the crisis of youth use of JUUL products.

4/8/2019: U.S. Senate launches investigation into JUUL Lab’s Marketing tactics.

July 24-25, 2019: U.S. Congress Oversight Committee Hearings on JUUL’s Role in Youth Nicotine Addiction Epidemic

THE FDA’S INVESTIGATION OF JUUL

In 2018, the FDA started investigating JUUL and its marketing practices. Below is a summary of the FDA findings on the e-cigarette maker and the demands the FDA made.

  • April 24, 2018 – The FDA demands JUUL Labs produce documents regarding JUUL’s marketing practices, market research, product design, public health impact, adverse events and complaints related to JUUL.
  • September 12, 2018 – The FDA conducts the largest coordinated enforcement activity in its history, focused on the sale of e-cigarettes to kids. The FDA issues warning letters and fines to more than 1,300 retailers for illegally selling JUUL and other vaping products to minors. FDA Commissioner Scott Gottlieb, M.D., said, “We see clear signs that youth use of electronic cigarettes has reached epidemic proportions.”The FDA’s letter read in part:

     

    On XX/XX/XXXX, an inspector representing the FDA completed an inspection of the establishment located at Address, City, State Zip Code. During this inspection, the establishment was in violation because you or your employee sold an e-liquid product to a minor and failed to check identification to verify purchaser’s age for a purchaser under the age of 27. This inspection revealed that the establishment sells, distributes, and/or advertises tobacco products, including e-liquid products, which requires that the establishment and its owners comply with federal laws and regulations governing such practices.

    The violations observed during the XX/XX/XXXX, inspection include the following:

    1. A minor was able to buy a JUUL e-liquid product on XX/XX/XXXX, at approximately XX:XX AM/PM in the establishment. A retailer must NOT sell covered tobacco products, such as e-liquid products, to a person younger than 18 years of age. Doing so violates 21 C.F.R. § 1140.14(b)(1) (2016).

    2. No one in the establishment checked the minor’s identification before the sale of a JUUL e-liquid product on XX/XX/XXXX, at approximately XX:XX AM/PM.

    You can see more details on the FDA website.

  • September 12, 2018 – The FDA sends a letter to JUUL demanding the company ‘take prompt action to address the rate of youth use of JUUL products.’; Demands ‘detailed plan to address and mitigate widespread use by minors.’; Demands ‘removing flavored products from the market…’The FDA tells JUUL they have 60 days to prove that they can keep their e-cigarette devices from getting into the hands of teens.
  • September 28, 2018 – The FDA conducts a surprise inspection of JUUL Labs and takes more than a thousand documents as it cracks down on the JUUL, vaping and e-cigarette addiction in youth. “The FDA will not tolerate a whole generation of young people becoming addicted to nicotine as a trade-off for enabling adults having unfettered access to these products [e-cigarettes]” FDA Press Conference October 2, 2018
  • October 25, 2018 – Howard A. Willard III, Chairman of Altria (a traditional cigarette manufacturer who makes Marlboro), writes a letter to FDA Commissioner Scott Gottlieb reassuring the Agency that the Company is ‘alarmed about the reported rise in youth e-vapor use to epidemic levels…’, and makes the following representations:
    • Altria will voluntarily remove its pod-based vaping products, MarkTen Elite and Apex by MarkTen, from the market ‘until…the youth issue is otherwise addressed.’
    • Altria will discontinue the sale of all other flavor variants [besides tobacco, menthol and mint].
    • “We believe pod-based products significantly contribute to the rise in youth use of e-vapor products.”
    • “Underage use of e-vapor products is further compounded by flavors in these products that go beyond traditional tobacco flavors.”
    • “These actions are essential to addressing the youth epidemic…”
  • December 20, 2018 – Just two months after Chairman Willard writes the letter to FDA concerned about the vaping epidemic in youth, Altria invests $12.8 billion in JUUL for a 35% share of JUUL Labs. Despite acknowledging concerns of pod-based vaping products causing an epidemic of youth nicotine addiction, and assurances to the contrary, to the FDA, Altria invests in the exact JUUL device that is causing the epidemic.Altria investment provides JUUL with ‘access to its premier innovative tobacco products retail shelf space…alongside combustible cigarettes.’ When consumers go into stores, now JUUL is prominently displayed next to the Marlboro man.Altria also provides JUUL with ‘its logistics and distribution experience to help JUUL expand its reach and efficiency and JUUL will have the option to be supported by Altria’s sales organization, which covers approximately 230,000 retail locations.’You can see the full details of the JUUL investment on its own website.
  • February 6, 2019 – The FDA sends a letter to JUUL demanding a meeting following Altria’s acquisition of major ownership of JUUL; Notice is given to JUUL that its actions are inconsistent with previous representations made to the FDA concerning addressing the crisis of youth use of JUUL products. FDA Commissioner Scott Gottlieb sends the letter directly to JUUL CEO Kevin Burns.FDA demands meeting with Altria Group CEO, Howard Willard, to explain why the company is expanding its distribution of nicotine to youth, despite the company’s commitments to the FDA, and the public, to the contrary. (2/6/19 FDA Letter from Scott Gottlieb, M.D. to Howard A. Willard, III.)

logos

What makes Laminack, Pirtle & Martines a successful litigation law firm?
One word: Commitment.

We promise a total commitment to fighting for compensation for victims of negligence.

Contact Info

  5020 Montrose Blvd, 9th Floor
Houston, TX 77006-6533

 713-292-2750

Toll Free: 800-805-2778

Fax: 713-292-2755

 This email address is being protected from spambots. You need JavaScript enabled to view it.